Pharmacogenomic Study of Androgenetic Alopecia

Androgenetic Alopecia Clinical Trial

Official title:

Pharmacogenomic Study of Androgenetic Alopecia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01227031
• Other study ID #: 98089
• Status: Not yet recruiting
• Phase: N/A
• First received: October 20, 2010
• Last updated: November 10, 2010
• Start date: October 2010
• Est. completion date: July 2011

Study information

• Verified date: October 2010
• Source: Taipei Medical University WanFang Hospital
• Contact: Ren-Yu Tsai
• Phone: 886-2-29307930
• Email: b671022[@]tmu.edu.tw
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

Androgenic alopecia, the common form of hair loss is a highly heritable disorder of considerable social significance affecting around 40% of adult men and women. A variety of genetic and environmental factors are likely to play a role in androgenetic alopecia. Genetic variants in the human androgen receptor gene (AR) have been reported to be associated with AGA in Caucasians. Other genes involved with hair loss also have been found. One of them being a gene on chromosome 3 (3q26). A recent genome-wide association study in 296 individuals with male-pattern baldness and 347 controls had carried out and five SNPs on chromosome 20p11 were found to be highly significant association for AGA (rs2180439 combined P = 2.7 x 10(-15)). No interaction was detected with the X-chromosomal androgen receptor locus, suggesting that the 20p11 locus has a role in a yet-to-be-identified androgen-independent pathway.

The total number of evaluated patients with androgenic alopecia will be at least 300. All patients will be further grouped as good responders or poor responders to conventional medications, such as topical minoxidil and systemic finasteride. Candidate genes potentially involved in gout and its treatment response will be selected from the published literatures; specifically, two resources of candidate genes will be selected: (i) genes which are known to directly link with androgenic alopecia, and (ii) genes are potentially implicated in particular pathways of androgen/estrogen receptors, metabolism and downstream signals, and genes involved in anti-oxidants or hair growth. The SNP genotyping will be performed by MALDI-TOF Mass Spectrometry. Data analysis will be performed by comparing SNPs allele frequency between good responder and poor responder to conventional medications of patients with androgenic alopecia and further comparing to the allele frequency of SNPs in healthy controls. A functional study will also be done to prove the genetic association.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 400
• Est. completion date: July 2011
• Est. primary completion date: October 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• Willing to sign inform consent form

• Willing to received history taking by telephone or interview

• Diagnosed androgenetic alopecia by Hamilton-Norwood classification

• More than 20 year-old, both sex

Exclusion Criteria:

• Ever had trauma over alopecia area

• Cancer, infection, or other systemic disease that might interfere diagnosis

• Unconfirmed diagnosis clinically or pathologically.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata
• Androgenetic Alopecia

Locations

Country	Name	City	State
Taiwan	Taipei Medical University-Wan Fang Hospital	Taipei

Sponsors (2)

Lead Sponsor	Collaborator
Taipei Medical University WanFang Hospital	Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan,